Ownership Action Don’t Lie: Erba Diagnostics Inc Sentiment Worsening on Low Stock Potential

November 21, 2016 - By Winifred Garcia   ·   0 Comments

Ownership Action Don't Lie: Erba Diagnostics Inc Sentiment Worsening on Low Stock Potential

Sentiment for Erba Diagnostics Inc (OTCMKTS:ERBA)

Erba Diagnostics Inc (OTCMKTS:ERBA) institutional sentiment decreased to 0 in Q2 2016. Its down -1.00, from 1 in 2016Q1. The ratio fall, as 2 investment professionals started new and increased stock positions, while 2 cut down and sold their equity positions in Erba Diagnostics Inc. The investment professionals in our partner’s database now own: 804,550 shares, down from 817,575 shares in 2016Q1. Also, the number of investment professionals holding Erba Diagnostics Inc in their top 10 stock positions was flat from 0 to 0 for the same number . Sold All: 2 Reduced: 0 Increased: 1 New Position: 1.

ERBA Diagnostics, Inc., through its subsidiaries, develops, makes and markets diagnostic test kits, or assays, and automated systems that are used to aid in the detection of disease markers primarily in the areas of autoimmune, infectious diseases, clinical chemistry, hematology and diabetes testing. The company has a market cap of $22.04 million. The Company’s divisions include Domestic and European. It currently has negative earnings. The domestic region contains its subsidiaries located in the United States and in Latin American and corporate operations.

The stock closed at $0.31 during the last session. It is down 6.00% since October 22, 2016 and is uptrending. It has outperformed by 2.14% the S&P500.

According to Zacks Investment Research, “ERBA Diagnostics, Inc. develops, manufactures and markets diagnostic test kits, or assays, and automated systems primarily for autoimmune and infectious diseases. The main subsidiaries of the company include: Diamedix Corporation, Delta Biologicals S.r.l. and ImmunoVision, Inc. ERBA Diagnostics, Inc., formerly known as IVAX Diagnostics, Inc., is headquartered in Miami, Florida.”

ERBA Company Profile

ERBA Diagnostics, Inc., incorporated on June 28, 1999, through its subsidiaries, develops, makes and markets diagnostic test kits, or assays, and automated systems that are used to aid in the detection of disease markers primarily in the areas of autoimmune, infectious diseases, clinical chemistry, hematology and diabetes testing. The Company’s divisions include Domestic and European. The domestic region contains its subsidiaries located in the United States and in Latin American and corporate operations. The European region contains its subsidiary located in Italy. The Company’s tests are based on a range of technologies, including Enzyme Linked ImmunoSorbent Assay (ELISA) technology, clinical chemistry, hematology and cell separation, as well as high performance liquid chromatography (HPLC) separations, all of which are clinical testing methodologies used across the world. It also creates and makes laboratory instruments that perform the tests. It also develops, makes and markets raw materials, such as antigens used in the production of diagnostic kits. The Company’s subsidiaries include Diamedix Corporation (Diamedix), ImmunoVision, Inc. (ImmunoVision), Delta Biologicals, S.r.l. (Delta Biologicals), Drew Scientific, Inc. (Drew Scientific) and JAS Diagnostics, Inc. (JAS Diagnostics).

More notable recent ERBA Diagnostics Inc (OTCMKTS:ERBA) news were published by: Globenewswire.com which released: “ERBA Diagnostics, Inc. Announces Non-Reliance on Previously Issued Financial …” on November 20, 2015, also Globenewswire.com with their article: “ERBA Diagnostics, Inc. Appoints Ernesina Scala as Chief Financial Officer and …” published on May 06, 2015, Globenewswire.com published: “ERBA Diagnostics, Inc. Announces Notice of Noncompliance With NYSE MKT …” on May 20, 2016. More interesting news about ERBA Diagnostics Inc (OTCMKTS:ERBA) were released by: Globenewswire.com and their article: “ERBA Diagnostics Inc. Annual General Meeting CEO’s Speech on the Company’s …” published on December 17, 2015 as well as Businesswire.com‘s news article titled: “ERBA Diagnostics, Inc. Appoints Mohan Gopalkrishnan as Chief Executive Officer …” with publication date: May 27, 2014.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Winifred Garcia


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>